Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 14

Results For "BIS"

189 News Found

Stelis receives recommendation from EMA granting market authorization for Kauliv
Drug Approval | November 14, 2022

Stelis receives recommendation from EMA granting market authorization for Kauliv

Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.


IOLCP receives EDQM certification to supply Pantoprazole Sodium Sesquihydrate API in Europe
News | November 07, 2022

IOLCP receives EDQM certification to supply Pantoprazole Sodium Sesquihydrate API in Europe

Pantoprazole Sodium Sesquihydrate are proton pump inhibitors used in drugs to suppress the gastric acid secretion


Syngene Q2 FY23 PAT up 11% to Rs. 102 Cr
News | October 20, 2022

Syngene Q2 FY23 PAT up 11% to Rs. 102 Cr

Revenue from operations up 26% to Rs. 768 crores


Cadila and CII launches joint national campaign for rabies-free India by 2030
Public Health | September 24, 2022

Cadila and CII launches joint national campaign for rabies-free India by 2030

Rabies claims around 59,000 deaths globally a year, of which around 20,000 or just over one-third of the deaths take place in India alone


MoU signed between Ministry of Ayush and MeitY
Policy | August 13, 2022

MoU signed between Ministry of Ayush and MeitY

MeitY will provide technical support for digitalisation of the Ayush Sector under the Ayush Grid project for a period of three years


PIB: Quality control of Ayush drugs
Policy | August 03, 2022

PIB: Quality control of Ayush drugs


Syngene reports revenue from operations up 8% in Q1 FY 23
News | July 21, 2022

Syngene reports revenue from operations up 8% in Q1 FY 23

Company raises the annual revenue guidance from mid-teens to high teens


Glenmark Pharma and SaNOtize announce Peer Reviewed Publication of its Phase 3 Clinical Trials on SaNOtize's Novel Nitric Oxide Nasal Spray
Clinical Trials | July 14, 2022

Glenmark Pharma and SaNOtize announce Peer Reviewed Publication of its Phase 3 Clinical Trials on SaNOtize's Novel Nitric Oxide Nasal Spray

The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.


Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China
News | July 01, 2022

Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China

Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia


MTPA announces long-term findings from post-marketing safety study of Radicava
News | June 30, 2022

MTPA announces long-term findings from post-marketing safety study of Radicava

Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone